Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The FDA approved PADCEV (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) or Keytruda QLEX as neoadjuvant then adjuvant perioperative treatment for adult patients with muscle‑invasive bladder cancer who are ineligible for cisplatin, based on pivotal Phase 3 EV‑303 (KEYNOTE‑905) results. The combination is being evaluated in cisplatin‑eligible MIBC in EV‑304 (KEYNOTE‑B15) and is already approved for locally advanced/metastatic urothelial cancer in the U.S., Japan and other markets (EU approval for platinum‑eligible la/mUC), while PADCEV also has single‑agent indications in later lines. Pfizer’s December 2023 acquisition of Seagen—whose PADCEV program was developed with Astellas and studied with Merck’s Keytruda—cements Pfizer’s position in urothelial cancer and paves the way for incremental perioperative uptake in a cisplatin‑ineligible patient population with an unmet need.

Analysis

The FDA approved PADCEV (enfortumab vedotin-ejfv) in combination with pembrolizumab (Keytruda) or Keytruda QLEX as neoadjuvant treatment continued after cystectomy as adjuvant therapy for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin, a decision explicitly tied to pivotal Phase 3 EV-303 (KEYNOTE-905) results. The article notes PADCEV plus pembrolizumab is under evaluation in cisplatin-eligible patients in EV-304 (KEYNOTE-B15) and that the combination already holds approvals for locally advanced/metastatic urothelial cancer in the U.S., Japan and other countries, with EU approval for platinum-eligible la/mUC; PADCEV also has single-agent indications in later lines.

Pfizer’s December 14, 2023 acquisition of Seagen gives Pfizer direct ownership of the PADCEV franchise and positions it to commercialize this new perioperative indication—this is reflected in a moderately positive market sentiment (sentiment_score 0.5; PFE per-ticker 0.6). The regulatory expansion addresses an unmet cisplatin-ineligible perioperative market and could drive incremental revenue and deeper oncology presence for Pfizer and Astellas, while Merck’s Keytruda remains a strategic partner in the combination (MRK per-ticker 0.4).

Key uncertainties remain: the article provides no efficacy magnitudes or absolute benefit figures from EV-303, so clinical uptake will depend on guideline endorsements, payer reimbursement decisions and real-world safety/efficacy, and the outcome of EV-304 will determine further label expansion to cisplatin-eligible patients; integration and launch execution risks post-Seagen acquisition are additional operational considerations.

Key Decisions for Investors

• Consider increasing relative exposure to Pfizer (PFE) to capture potential upside from PADCEV's new perioperative indication and the Seagen acquisition, while monitoring execution of the commercial launch
• Monitor EV-304 (KEYNOTE-B15) readout, published efficacy/safety metrics from EV-303 and early real-world uptake and reimbursement decisions as the primary near-term catalysts
• Maintain a measured view on Merck (MRK): Keytruda stands to benefit strategically from combination use but exposure is indirect—avoid sizing positions based solely on this approval
• Account for execution and reimbursement risks by staging new positions or using hedges until clear commercial adoption and guideline incorporation are observed